View Post

Propanc Biopharma Initiates Development of Bio-Analytical Assay in Preparation for Human Trials

In Clinical Trials by Barbara Jacoby

From: prnewswire.com Feasibility Study Intends to Quantify PRP’s Active Ingredients in Human Serum Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that it has initiated development of a bio-analytical assay intended to quantify the active ingredients of the company’s lead product candidate, PRP, in preparation …

View Post

Intraoperative radiotherapy viable for certain patients with breast cancer

In Clinical Trials by Barbara Jacoby

By: Jennifer Southall From: healio.com Intraoperative radiotherapy remains a viable option for patients with low-risk breast cancer, according to a presenter at Miami Breast Cancer Conference. “Intraoperative radiotherapy has been used for at least 10 to 15 years and, in appropriately selected patients, published results of the treatment are quite good,” Frank A. Vicini, MD, FACR, FABS, FASTRO, radiation oncologist …

View Post

FDA suggests letting more patients with viral infections into cancer clinical trials

In Clinical Trials by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com A draft guidance, not yet implemented, suggests allowing more patients with hepatitis B and C and HIV into oncology clinical trials from which they are currently excluded. On the pages of oncology clinical trials on the database ClinicalTrials.gov, the section listing the various criteria that patients must meet for enrollment commonly includes a line stating …

View Post

Should Patients Have to Pay for the Drugs They Helped Test?

In Clinical Trials by Barbara Jacoby

By: Len Lichtenfeld, M.D. From: curetoday.com Here is an interesting situation that I learned about recently, and it has me asking a question I hadn’t thought of before: What is our obligation to those who participated in and benefited from clinical trials but then are charged huge copays to continue taking the drugs they helped develop when the medi­cines get …

View Post

U of S ‘assassin antibody’ shows promise in killing cancer

In Clinical Trials by Barbara Jacoby

By: Chris Vandenbreekel From: .cjme.com A promising research breakthrough at the University of Saskatchewan could end up being a cure for colorectal cancer. A research team has developed an “assassin antibody” that attaches itself to colorectal cancer cells and destroys them with an astonishing success rate. “We’ve had up to 80 per cent of animals completely disease free,” research lead …

View Post

Decision support helps Oregon Health personalize care

In Clinical Trials by Barbara Jacoby

By: Joseph Goedert From: healthdatamanagement.com   Oregon Health & Science University is using decision support software from Via Oncology to give physicians point-of-care and evidence-based care pathway recommendations. The technology also better enables the organization, specifically it’s Knight Cancer Institute, to connect patients to locally available clinical trials. Studies have shown that fewer than one in 20 adults with cancer …

View Post

Research to remove exclusions on immunotherapy

In Clinical Trials by Barbara Jacoby

By: Michael Hardy From: mdanderson.org People used to ask Patrick Hwu, M.D., why he decided to devote his career to melanoma, a skin cancer with high mortality rates and limited treatment options. “They would come up to me and say, ‘How can you treat advanced melanoma? Isn’t that depressing?’ And actually, it was — my clinic of advanced melanoma patients …

View Post

Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study

In Clinical Trials by Barbara Jacoby

By: GlobeNewswire From: nasdaq.com Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that target enrollment of 360 patients in the Oraxol Phase III clinical trial in metastatic breast cancer has been achieved on schedule. Athenex also reaffirms that top line data from …

View Post

Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Carboplatin in Patients with Advanced or Metastatic Solid Tumors

In Clinical Trials by Barbara Jacoby

Source: Deciphera Pharmaceuticals, Inc. From: apnews.com Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has initiated an open-label, multicenter, Phase 1b/2 study of rebastinib, the Company’s investigational small molecule switch control inhibitor of TIE2 kinase, in combination with carboplatin in patients with advanced or metastatic solid tumors. …

View Post

Researchers Suggest Current Methods for Reporting Toxicities in Cancer Clinical Trials are Falling Short

In Clinical Trials by Barbara Jacoby

Findings published in JNCCN examine the differences between patient- and clinician-reported outcomes; recommend a greater focus on the cumulative effect of multiple low-level toxicities. New research from Europe, published in the December 2018 issue of JNCCN—Journal of the National Comprehensive Cancer Network, finds that quality-of-life for people with cancer is reduced by an accumulation of low-level toxicities just as much …